Used in targeted cancer therapies, particularly in inhibiting tumor angiogenesis and vascular development in solid tumors. It blocks the EphB4 receptor signaling pathway, which plays a key role in tumor growth and metastasis, especially in breast, prostate, and lung cancers. This antibody is also being explored for its potential in disrupting tumor-associated blood vessels, thereby enhancing the efficacy of chemotherapy and radiation. Additionally, it serves as a research tool for studying EphB4-mediated signaling in vascular biology and oncology.